Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients

Sollini, Martina; Farioli, Daniela; Froio, Armando; Chella, Antonio; Asti, Mattia; Boni, Roberto; Grassi, Elisa; Roncali, Massimo; Versari, Annibale; Erba, Paola Anna

doi:10.1097/jto.0b013e318293f051

Cited by 29 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main target and hotspot of lung cancer research is to pursue early diagnosis and proper selection of drugs and adjuvant treatment according to pathogenesis of lung cancer, thus improving the survival rate and quality of life of cancer patients (13–15). Moreover, except for deep investigations into lung cancer, little is known about the accurate mechanisms of pathogenesis and metastasis of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

et al. 2017

View full text Add to dashboard Cite

The expression of microRNA-215 (miR-215) in non-small cell lung cancer (NSCLC) tissues and the effects of miR-215 on the proliferation and migration of NSCLC cells were investigated. qRT-PCR was used to detect the expression of miR-215 in NSCLC tissues and paired normal tumor-adjacent lung tissues; MTT assay, transwell assay and soft-agar assay were used in vitro to evaluate the role of miR-215 on proliferation, migration and cell clonality on NSCLC cells, after transfecting miR-215 mimics to NSCLC cell line A549 or miR-215 to H1299. miR-215 was significantly decreased in NSCLC tissues compared to the paired normal tissues; Overexpression of miR-215 in A549 cells resulted in reduction of the cell proliferation, migration and cell clonality, while downregulation of miR-215 in H1299 cells could promote cell proliferation, migration and clonality. In conclusion, miR-215 was downregulated in NSCLC tissues and may play a key role in the development of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Given the high relapse rate of SCLC after 1 st line chemotherapy as well as the modest response rates to subsequent treatments, a new approach to the patient with relapsed/refractory SCLC is urgently needed. In addition to conventional chemotherapeutic agents including anthracycline-based regimes, topotecan or amrubicin [ 19 ], peptide receptor radionuclide therapy using radiolabelled somatostatin receptor ligands has been performed with rather modest success rates [ 20 , 21 ]. Important prerequisites to receptor-targeted therapies are a robust expression of the target receptor as well as a specific receptor binding.…”

Section: Discussionmentioning

confidence: 99%

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience

et al. 2016

View full text Add to dashboard Cite

Chemokine receptor CXCR4 is a key factor for tumor growth and metastasis in several types of human cancer. This study investigated the feasibility of CXCR4-directed imaging of small cell lung cancer (SCLC) with positron emission tomography/computed tomography (PET/CT) using the radiolabelled chemokine ligand [68Ga]Pentixafor.10 patients with primarily diagnosed (n=3) or pre-treated (n=7) SCLC (n=9) or large cell neuroendocrine carcinoma of the lung (LCNEC, n=1) underwent [68Ga]Pentixafor-PET/CT. 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG, n=6) and/or somatostatin receptor (SSTR)-directed PET/CT with [68Ga]DOTATOC (n=5) and immunohistochemistry (n=10) served as standards of reference.CXCR4-PET was positive in 8/10 patients and revealed more lesions with significantly higher tumor-to-background ratios than SSTR-PET. Two patients who were positive on [18F]FDG-PET were missed by CXCR4-PET, in the remainder [68Ga]Pentixafor detected an equal (n=2) or higher (n=2) number of lesions. CXCR4 expression of tumor lesions could be confirmed by immunohistochemistry.Non-invasive imaging of CXCR4 expression in SCLC is feasible. [68Ga]Pentixafor as a novel PET tracer might serve as readout for confirmation of CXCR4 expression as prerequisite for potential CXCR4-directed treatment including receptor-radio(drug)peptide therapy.

show abstract

“…One such tracer is radioactive octreotide, intended to harness the neuroendocrine properties of SCLC. While some brain metastases not evident on MRI were detected via the octreotide scans, its low sensitivity did not validate it as a clinical tracer [ 53 , 54 ]. Mono amino acid radiotracers such as L-[ 11 C]methyl-methionine (MET), [ 18 F]fluoroethyl-tyrosine (FET), [ 18 F]fluoro-L-dopa (FDOPA) and α-[ 11 C]methyl-L-tryptophan (AMT) may provide superior contrast to FDG given their lower physiologic uptake in the brain.…”

Section: Introductionmentioning

confidence: 99%

State-of-the-art considerations in small cell lung cancer brain metastases

et al. 2017

View full text Add to dashboard Cite

BackgroundSmall cell lung cancer (SCLC) frequently leads to development of brain metastases. These unfortunately continue to be associated with short survival. Substantial advances have been made in our understanding of the underlying biology of disease. This understanding on the background of previously evaluated and currently utilized therapeutic treatments can help guide the next steps in investigations into this disease with the potential to influence future treatments.DesignA comprehensive review of the literature covering epidemiology, pathophysiology, imaging characteristics, prognosis, and therapeutic management of SCLC brain metastases was performed.ResultsSCLC brain metastases continue to have a poor prognosis. Both unique aspects of SCLC brain metastases as well as features seen more universally across other solid tumor brain metastases are discussed. Systemic therapeutic studies and radiotherapeutic approaches are reviewed.ConclusionsA clearer understanding of SCLC brain metastases will help lay the framework for studies which will hopefully translate into meaningful therapeutic options for these patients.

show abstract

Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients

Abstract: Radiolabeled SST-analog PET/CT demonstrated enhanced SSTR expression in 50% of cases. Nevertheless, PRRT in ED-SCLC was ineffective, suggesting the need to anticipate or combine PRRT in a multimodality approach.

Cited by 29 publications

References 12 publications

miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience

State-of-the-art considerations in small cell lung cancer brain metastases

Contact Info

Product

Resources

About